COMPANY

Totus Medicines

HQ: South San Francisco, CA source · totusmedicines.com ↗

Keywords: small molecule oncology immunology HR+/HER2-negative Breast Cancer TOS-358

Location: South San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Feb 15, 2023 Trial start Phase 1: A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer source ↗

2027-12 (ESTIMATED) · Phase 1 · A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer · NCT05683418

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT05683418	A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer	Phase 1	Recruiting	Feb 15, 2023	2027-12 (estimated)